blood®
Erratum

Check for updates

Mannes M, Dopler A, Zolk O, et al. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity. *Blood*. 2021;137(4):443-455.

In Figure 1A on page 445, an error was introduced during the publication process. The green label "AP" should be "CP." The corrected Figure 1A is shown below.



Figure 1. Strong CP activation leads to hemolysis despite C3 peptide inhibitor Cp40. (A) CP- and AP-mediated lysis in presence of Cp40. A total of 80% NHS naturally containing antibodies against the Forssman antigen (which is present on shRBCs) was mixed with Cp40 to obtain final Cp40 concentrations of 0.25 to 16 μM, as indicated. AP activity was determined by mixing rabbit erythrocytes with 80% NHS supplemented with 5 mM Mg-EGTA in the presence of the same range of Cp40 concentrations. A serum mix with phosphate-buffered saline (PBS) instead of Cp40 served as positive control, whereas 5 mM EDTA and 5 mM Mg-EGTA dissolved in PBS (in case of CP; for each final concentration) served as negative controls (PBSE, PBS containing EDTA). Released hemoglobin was measured as a marker of hemolysis (average of 3 independent assays with standard deviation [SD] is shown).

https://doi.org/10.1182/blood.2024024193

© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Downloaded from http://ashpublications.net/blood/article-pdf/143/17/1783/2223033/blood_bld-2024-024193-main.pdf by guest on 06 May 2024